UroGen Pharma(URGN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenues for the year ended December 31, 2025, were $109.8 million, a 21% increase from $90.4 million in 2024, driven by the commercial launch of Zusduri and increased sales of Jelmyto [19] - Net loss for 2025 was $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share in 2024 [21] - Cash equivalents and marketable securities totaled $120.5 million as of December 31, 2025 [21] Business Line Data and Key Metrics Changes - Zusduri generated $15.8 million in revenue for 2025, reflecting early launch dynamics [5] - Jelmyto generated net product revenue of $94 million for the full year 2025, indicating continued underlying demand growth [7][17] Market Data and Key Metrics Changes - As of December 31, 2025, there were 838 activated sites of care for Zusduri, with 102 unique prescribers and 32 repeat prescribers [15] - Over 95% of covered lives had open access to Zusduri by year-end 2025, facilitating broader adoption [15] Company Strategy and Development Direction - The primary focus is on the commercial launch of Zusduri, which addresses a large and underserved market, with potential peak revenue exceeding $1 billion [5][7] - The company is advancing its pipeline, including UGN-103 and UGN-104, with plans for NDA submissions and potential FDA approvals in 2026 and 2027 [8][12] - A refinancing agreement with Pharmakon Advisors has strengthened the balance sheet and enhanced financial flexibility, supporting ongoing initiatives [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early trajectory of Zusduri's launch, with key indicators showing acceleration in prescriber engagement and patient access following the implementation of a permanent J-code [5][15] - The company anticipates narrowing conversion timelines from patient enrollment to dosing as sites gain familiarity with the product [16] Other Important Information - The company is not providing formal sales guidance for Zusduri in 2026 due to its early launch stage but expects to offer guidance after gaining visibility into steady-state demand [29] - Operating expenses for 2026 are expected to be in the range of $240 million to $250 million, driven by sales force expansion and lifecycle management plans [24] Q&A Session Summary Question: Insights on patient enrollment forms and potential guidance for Zusduri - Management indicated that they expect to provide formal guidance for Zusduri at least two quarters post the permanent J-code implementation [29] - There has been a noticeable increase in key indicators, including patient enrollment forms, since the J-code became effective [31][32] Question: Trends in repeat prescribers and feedback from new prescribers - There is steady growth in both new and repeat prescribers, with positive experiences leading to increased confidence in reimbursement [38] - New prescribers are waiting for clean claim submissions and reimbursement confidence before becoming repeat prescribers [38] Question: Timing for UGN-103 market introduction and its relationship with Zusduri - UGN-103 is expected to be introduced after obtaining a permanent J-code, likely in early 2028 [40][41] Question: Current use patterns for Zusduri among patients - Zusduri is primarily used for patients who recur early, have frequent recurrences, or are unfit for surgery, with enthusiasm from physicians regarding its efficacy [47] Question: Opportunities for Zusduri in the adjuvant setting - There is interest in exploring Zusduri in the adjuvant setting for high-risk disease, with ongoing protocol finalization for trials [59][60]